Tag
In Finnish adults with type 1 diabetes, STEMI and NSTEMI showed distinct incidence trends and risk profiles. NSTEMI was more common overall and linked to dyslipidemia and advanced microvascular disease, whereas impaired eGFR tracked more wi
This study identifies Annexin A2 as a critical negative regulator of PHB2-mediated mitophagy in myocardial infarction. By promoting PHB2 degradation via the TRIM29 ligase, ANXA2 exacerbates cardiac injury. Inhibiting ANXA2 restores mitochon
Researchers identify Annexin A2 as a key inhibitor of mitophagy in the heart. By blocking the mitophagy receptor PHB2, ANXA2 exacerbates cardiac injury after myocardial infarction. This study demonstrates that targeting ANXA2 restores mitoc
This phase 2 trial demonstrates that varenicline, a partial nAChR agonist, significantly reduces premature ventricular complexes and nonsustained ventricular tachycardia in post-myocardial infarction patients, offering a novel therapeutic t
The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor b
Recent research reveals that the common ALDH2 rs671 genetic variant significantly enhances platelet activation and arterial thrombosis through aldehyde accumulation, reactive oxygen species, and ACAD10-mediated mitophagy, identifying ALDH2
Patients with myocardial infarction due to isolated coronary artery ectasia face a significantly higher risk of recurrent MI and stent thrombosis compared to those without ectasia, highlighting the need for specialized long-term management.
A retrospective study reveals that patients with myocardial infarction caused by isolated coronary artery ectasia face significantly higher risks of recurrence and stent thrombosis compared to those without ectasia, highlighting a critical
Researchers have discovered that the protein PRMT9 plays a vital role in healing the heart after a myocardial infarction by controlling inflammatory macrophages. By promoting the degradation of the STAT1 protein, PRMT9 reduces tissue damage
This review explores the discovery of a two-phase specialization process where CCR8+ regulatory T cells, recruited via the macrophage-derived CCL1 axis, mitigate inflammation and promote cardiac repair following myocardial infarction.
Recent data from the TUXEDO-2 and ISAR-REACT 5 trials suggest prasugrel may provide superior outcomes over ticagrelor in high-risk PCI patients, including those with diabetes and STEMI.
A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without incre
A robust Mendelian randomization study demonstrates that the reduced risk of myocardial infarction associated with GLP-1 receptor agonists is primarily mediated by improvements in HbA1c, BMI, and lipid profiles, rather than direct cardiac e
A comprehensive analysis of over 10,000 patients identifies key risk factors for post-PCI troponin increase, highlighting the protective role of intravascular imaging and the prognostic impact of different myocardial infarction definitions.
Switching from high-sensitivity troponin I to T significantly increases diagnoses of myocardial injury and hospital admissions without improving long-term cardiovascular outcomes, while low-threshold troponin I remains a safe tool for rapid
A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.
A phase 3 randomized trial found intracoronary infusion of allogeneic Wharton’s jelly mesenchymal stem cells (WJ-MSCs) after STEMI reduced new-onset heart failure and HF readmissions and improved LVEF versus standard care over a median 33-m
Emerging cohort evidence reveals myocardial infarction significantly elevates late-onset epilepsy risk, with late-onset epilepsy also predicting subsequent myocardial infarction and vascular mortality, underscoring shared systemic vascular
In a randomized phase 2 trial, the anti‑LOX‑1 antibody MEDI6570 lowered circulating sLOX‑1 and IL‑6 but failed to reduce noncalcified coronary plaque volume versus placebo in post‑MI patients with residual inflammation.
An individual‑patient meta‑analysis of five randomized trials (n=17,801) found that beta‑blocker therapy did not reduce death, recurrent MI, or heart failure in patients with recent myocardial infarction and LVEF ≥50% without other indicati
